XNAS · Healthcare · Biotechnology
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Q4 2025 | -0.03 | -0.20 | -566.67% | $0 | ❌ Miss | +1.67% | -19.81% | -25.96% |
| 2024-08-30 | Q2 2024 | -0.15 | -0.16 | -6.67% | $0 | ❌ Miss | -3.08% | -2.31% | +29.23% |
| 2024-06-14 |
| Q1 2024 |
| -0.18 |
| -0.22 |
| -22.22% |
| $0 |
| ❌ Miss |
| -4.79% |
| -6.85% |
| -3.42% |
| 2024-03-29 | Q4 2023 | -0.28 | -0.48 | -71.43% | $0 | ❌ Miss | — | — | — |
| 2023-11-09 | Q3 2023 | -0.39 | -0.32 | +17.95% | $0 | ✅ Beat | +2.29% | -0.57% | -5.71% |
| 2023-09-01 | Q2 2023 | -0.46 | -0.37 | +1956.52% | $0 | ✅ Beat | -0.85% | -6.38% | -34.04% |
| 2023-06-16 | Q1 2023 | — | -0.39 | — | $0 | — | -1.04% | -5.90% | -19.79% |
| 2023-04-10 | Q4 2022 | -0.34 | -0.39 | -14.71% | $0 | ❌ Miss | -8.20% | -5.41% | -6.56% |
Showing last 8 quarters.